More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

A new study by researchers at Unity Health, Sunnybrook Health Sciences Center and the University of Toronto has found that ...

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

MUSCAT: The National Programme for Early Detection of Diabetic Retinopathy using artificial intelligence (AI) technologies ...

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

Diabetic retinopathy is the leading cause of blindness in working-age adults in the U.S. and is a complication of diabetes.